Please use this identifier to cite or link to this item:
|Title:||New Agents for the Treatment of Type 2 Diabetes.||Austin Authors:||Libianto, Renata;Ekinci, Elif I||Affiliation:||Department of Endocrinology, Austin Health, Heidelberg, Victoria, Australia
Department of Medicine, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australia
|Issue Date:||Apr-2019||metadata.dc.date:||2019-01-23||Publication information:||Critical care clinics 2019; 35(2): 315-328||Abstract:||The Renaissance of glucose-lowering therapies has arrived with multiple agents that lower blood glucose and demonstrate cardiovascular and renal benefits in people with type 2 diabetes. This article summarizes these new classes of therapies, including the sodium glucose co-transporter-2 inhibitors, glucagon-like peptide-1 agonists, and dipeptidyl peptidase-4 inhibitors. Their cardiovascular safety profile, effects on glycemic, weight, and renal outcomes are discussed. As more options become available to treat type 2 diabetes, clinicians need to be aware of the advantages of each class of medications, beyond their glycemic lowering effects. The safety profiles are summarized in this article.||URI:||http://ahro.austin.org.au/austinjspui/handle/1/20297||DOI:||10.1016/j.ccc.2018.11.007||ORCID:||0000-0003-2372-395X||PubMed URL:||30784612||Type:||Journal Article||Subjects:||DPP-4 inhibitors
|Appears in Collections:||Journal articles|
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.